Search alternatives:
largest decrease » larger decrease (Expand Search)
marked decrease » marked increase (Expand Search)
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
largest decrease » larger decrease (Expand Search)
marked decrease » marked increase (Expand Search)
mg decrease » _ decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Raw Data.
Published 2025“…Ninety-six 12-week-old minks were randomly assigned to six groups (0, 100, 200, 300, 400, or 500 mg/kg COS), with 8 replicates per treatment and 2 minks per replicate, for an 8-week trial. …”
-
10
Loxoprofen and SB225002 administration decreased sound stress exposure-induced hyperalgesia.
Published 2025“…Mice treated with loxoprofen (500 mg/kg) or SB225002 (3 mg/kg) showed significantly decreased response times to the filament compared to Stress + saline group (Stress + loxoprofen (500 mg/kg), 30 min after administration, **<i>P</i> < 0.01, 60 min after administration, ***<i>P</i><i> <i><</i> </i>0.001; Stress + SB225002 (3 mg/kg), 60 min after administration, *<i>P</i> < 0.05). 2-way ANOVA <i>post-hoc</i> Bonferroni test. …”
-
11
-
12
-
13
-
14
-
15
-
16
-
17
Data Sheet 1_Empagliflozin’s cardioenergetic protective effects through PPARα pathway modulation in heart failure.pdf
Published 2025“…Post-treatment, MRGlu and glucose uptake decreased markedly in the empagliflozin (EMPG) group, while no significant changes were observed in the fenofibrate (FF) group. …”
-
18
-
19
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
-
20
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”